Аннотация
Purpose of the study: to analyze the use of inclisiran in real clinical practice for primary and secondary prevention of atherosclerotic cardiovascular diseases in patients with dyslipidemia.
Methods: a retrospective analysis of the treatment data was conducted for the first 20 patients who received two doses of inclisiran. The review covered medical history, physical examination data, additional lipid-lowering therapy, genetic testing, lipid profile data, lipoprotein (a) level, standard biochemical tests at baseline, after 2 and 4 months from the start of inclisiran therapy.
Results: after starting treatment with inclisiran, average total cholesterol (TC) decreased: after 2 months by 41.0% from 5.1 (4.13; 6.47) to 3.01 (2.77; 4.27) mmol/L, after 4 months by 44.7% of the initial level to 2.82 (2.46; 3.44) mmol/L (compared to initial levels p < 0.001). The significant decrease of low-density lipoprotein cholesterol (LDL) level was also archived: after 2 months by 47.1% from 3.08 (2.40; 4.73) to 1.63 (1.10; 2.60) mmol/L; after 4 months by 54.5% from initial levels to 1.4 (0.87, 1.90) mmol/L L (compared to initial levels p < 0.001). The average triglyceride levels by the 4th month of observation decreased by 27.9%. And a decrease in LP (a) levels by 27.8% was registered after 2 months of observation.
Conclusion: the use of inclisiran in real clinical practice is accompanied by a significant decrease in serum total cholesterol, LDL cholesterol, TG and LP (a) with good tolerability and high efficiency.
Процитировать:
E. A. Polyakova, Yu. Sh. Khalimov, S. V. Lapin, T. M. Bakher, A. V. Mazing, A.K. Musonova, V.D. Nazarov., (2025) “First Results Of The Use Of Inclisiran In Patients With Dyslipidemia In Real Clinical Practice.” journal of clinical cardiology interventions, 5(2). DOI: 10.61148/2836-077X/JCCI/054.